The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2020 | The impact of COVID-19 on CLL disease management
Robin Foà, MD, Sapienza University of Rome, Rome, Italy, discusses how the COVID-19 pandemic has impacted the care of chronic lymphocytic leukemia (CLL) patients. From a survey conducted with the CAMPUS program, the results indicated that surprisingly few CLL patients were symptomatic and tested positive. However, the COVID-19 pandemic has had an impact on the management of disease as well. Treatment has been delayed or changed and clinical trial recruitment has been affected. This interview took place during the European Research Initiative on CLL (ERIC) International Virtual Meeting 2020.
